CompletedPhase 4

PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation

Netherlands92 participantsStarted 2005-07

Plain-language summary

Randomized, double blind, placebo controlled, prospective trial investigating the effect of erythropoietin in renal transplantation. The investigators postulate that erythropoietin reduces the risk of delayed graft function.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients * Receiving a kidney from a non-heart-beating donor category 3 Exclusion Criteria: * Donor related factors: a prolonged warm ischaemic time (\> 45 min); a cold ischaemic time of \> 24 hours; serum creatinin of \> 150 umol/l

What they're measuring

incidence of delayed graft function and primary non function after kidney transplantation

Timeframe: within12 weeks after transplantation

Trial details

NCT IDNCT00157300

SponsorLeiden University Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Patients Receiving a Kidney From a Non-Heart-Beating Donor trials